What SeQuent Scientific does

SeQuent Scientific Limited, now operating as Viyash Scientific Limited following its January 2026 rebranding, is an Indian-headquartered, publicly listed (NSE/BSE) integrated pharmaceutical enterprise built around four business verticals: Active Pharmaceutical Ingredients (API), Human Health finished dosage formulations, Animal Health products, and CDMO services. The company was founded in 1985, is headquartered in Hyderabad, and was historically backed by Carlyle Group. Its manufacturing footprint spans 15+ facilities across four continents with total reactor capacity of 2,300 KL+, multi-scale reactor capability from 100 L to 15 KL, and dedicated suites for high-potency APIs (HPAPI) and cytotoxic (OEB 4/5) products.

The technology platform emphasizes complex chemistry, custom synthesis, and regulatory-grade manufacturing, supported by LIMS-enabled digital quality systems, advanced analytical instrumentation, and 190+ filed patents. The company holds approvals from USFDA, EU-GMP, WHO GMP, EDQM, ANVISA, NMPA China, PMDA, MFDS Korea, COFEPRIS, TGA Australia, and Health Canada; in August 2024 it received WHO prequalification for its Albendazole API, enabling supply into UN agency global health programs. The combined entity is described as India's first and largest globally integrated animal health company and one of the Top 25 animal health companies globally.

The business model is B2B enterprise pharmaceutical manufacturing with quote-based, multi-year contracts. Revenue is generated through API sales, finished dosage formulation supply, veterinary pharmaceuticals, and CDMO services (custom synthesis and contract manufacturing). Customers are global pharmaceutical manufacturers; pricing is not publicly disclosed. In September 2024 SeQuent announced a strategic merger with Viyash Lifesciences valued at ₹8,000 crore; NCLT approved the merger in November 2025 and the combined entity was renamed Viyash Scientific Limited in January 2026, operating across 150+ countries with FY26 revenue of ₹34,203 million.

Name

SeQuent Scientific

Legal name

Viyash Scientific Ltd.

Website

https://sequent.in

Company type

Public

Founded year

1985

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Viyash Scientific Limited (formerly SeQuent Scientific) is an Indian integrated pharmaceutical enterprise operating four verticals — API, Human Health formulations, Animal Health, and CDMO services — across 150+ countries, serving global pharmaceutical manufacturers from 15+ manufacturing facilities in India and abroad.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Active pharmaceutical ingredients
• Animal health pharmaceuticals
• Finished dosage formulations
• Contract manufacturing services
• Veterinary pharmaceutical products

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Manufacturing and Sales: Active Pharmaceutical Ingredients manufactured to highest global standards sold to pharmaceutical companies worldwide. Includes both Human API and Animal API products with regulatory-accredited manufacturing facilities.
2. Human Health Formulations: End-to-end FDF (Finished Dosage Formulation) development and manufacturing including USFDA compliant facilities, ANDA filing, IP evaluation and pharmacovigilance services.
3. Animal Health Products: Veterinary pharmaceuticals including animal health APIs and finished dosage formulations. India’s first & largest global integrated animal health company, among Top 25 animal companies globally.
4. CDMO Services: Contract development and manufacturing organization services including custom synthesis, dedicated HPAPI/cytotoxic handling, and analytical support.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

SeQuent Scientific is an integrated pharmaceutical enterprise that manufactures and sells Active Pharmaceutical Ingredients (APIs), finished dosage formulations for human and animal health, and provides contract development and manufacturing (CDMO) services. The company operates 15+ manufacturing facilities across four continents with a capacity of 2,300 KL+, supplying global pharmaceutical manufacturers and veterinary health companies. It is positioned among the Top 25 animal health companies globally and serves customers in over 150 countries.

Product overview

Viyash Scientific Ltd. (formerly SeQuent Scientific following the merger with Viyash Lifesciences) is an integrated pharmaceutical enterprise with four core business verticals: API (Active Pharmaceutical Ingredients), Human Health, Animal Health, and CDMO Services. The company operates across the pharmaceutical value chain from API manufacturing to finished dosage formulations, with manufacturing facilities across multiple continents serving customers in numerous countries.

Differentiator

Problem solved

Functional benefit

Products and services

• API (Active Pharmaceutical Ingredients) Active Pharmaceutical Ingredients manufactured to the highest global standards with regulatory accredited manufacturing facilities, multi-scale reactor capabilities (100 Liter to 15 KL), and manufacturing capacity of 2,300 KL+. Sold to pharmaceutical manufacturers worldwide for both human and animal applications.
• Human Health Formulations Comprehensive pharmaceutical solutions for improving human healthcare, including end-to-end Finished Dosage Formulation (FDF) development and manufacturing with USFDA compliant facilities, ANDA filing, IP evaluation, and pharmacovigilance services.
• Animal Health Products Veterinary pharmaceuticals ensuring animal wellness and productivity, including animal health APIs and finished dosage formulations. GMP approved facilities with strong R&D and quality control; products include parasiticides, anti-infectives, and specialty formulations.
• CDMO Services End-to-end contract development and manufacturing services offering custom synthesis capabilities, dedicated suite to handle OEB 4/5 products, dedicated block for HPAPI/cytotoxic APIs, and advanced analytical instrumentation for product development and characterization.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Virbac: Global animal health company specializing in veterinary parasiticides, vaccines, and APIs with similar geographic spread; comparator on animal health end-market exposure.
• Phibro Animal Health: Global animal health pharmaceutical company with comparable parasiticide, anti-infective, and animal nutrition lines; one of the most direct comparables in the integrated animal health + API manufacturing space, similar size profile and geographic reach.
• Divi's Laboratories: Indian pure-play API and CDMO manufacturer with comparable multi-vertical small-molecule platform and global regulatory footprint (USFDA, EU-GMP); closest Indian peer on the human health API/CDMO side of the business.
• Dechra Pharmaceuticals: Specialty animal health company focused on veterinary APIs and formulations across companion and livestock species; direct peer in the animal pharma market and similar mid-cap profile.
• Jubilant Pharmova: Indian pharma company with CDMO services, API manufacturing, and radiopharmaceuticals; comparable on multi-site manufacturing, complex chemistry capability, and CDMO contract structure.
• Laurus Labs: Indian API and CDMO manufacturer with comparable small-molecule platform, multi-vertical product mix (ARV APIs, onco APIs, animal health), and emerging CDMO business; similar mid-cap growth profile.

Emerging players

• Neogen Corporation: Animal health and food safety company with veterinary pharmaceutical and diagnostic offerings; thematic peer in the animal health end-market with overlapping customer base (producers and veterinarians).

Broad incumbents

• Piramal Pharma: Indian pharma with significant CDMO services across complex APIs and HPAPI; comparable on contract manufacturing, regulated markets exposure, and integrated operating model.
• Zoetis: World's largest pure-play animal health company producing APIs, parasiticides, vaccines, and diagnostics; comparable end-markets (livestock + companion animal) and supply chain model, though significantly larger and brand-led.
• Aurobindo Pharma: Large Indian pharmaceutical company with substantial API manufacturing capacity and global finished dosage reach; comparable on scale, regulatory approvals, and integrated API + formulation model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/viyash-life-sciences-pvt-ltd

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SeQuent Scientific